![]() |
"We are confident that Craig's leadership will drive Volpara's continued success and innovation in breast health," said Brandon Suh, CEO of Lunit. "His deep understanding of Volpara's business and his proven leadership make him the ideal person to guide the company into its next phase of growth. We look forward to his continued success in driving Volpara's mission to advance breast health solutions worldwide."
"I am honored to step into this role and continue leading Volpara's mission to transform breast health through innovative AI-powered solutions," said Craig. "Having been part of Volpara's journey for nearly a decade, I look forward to working with our talented team, partners, and customers to expand our impact and drive even greater value in breast cancer detection and patient care."
Craig, who has worked across South Africa, New Zealand, the Bahamas, and the United States, is a qualified Chartered Accountant and previously held roles at Ernst & Young (EY) and Deloitte before joining Volpara. He holds a Bachelor of Commerce in Accounting and Finance and an Accounting Higher Diploma from the University of Witwatersrand in Johannesburg, South Africa.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
About Volpara Health
Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara's software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.